TrialBlood2011

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Jonathan W Friedberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.